Purple Biotech (PPBT) vs Redhill Biopharma (RDHL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Redhill Biopharma is the larger company by market cap ($2.5 million vs $1.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PPBT | RDHL |
|---|---|---|
| Share price | $1.53 | $0.281 |
| Market cap | $1.86M | $2.50M |
| 1-day change | -4.09% | -13.08% |
| Forward P/E | — | 9.37 |
| EPS (TTM) | $-47.64 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $8.04M |
| Revenue growth (YoY) | — | +23.17% |
| Net income (latest FY) | $-26.39M | $-8.27M |
| Gross margin | — | 60.31% |
| Operating margin | — | -181.69% |
| Net margin | — | -102.80% |
| 52-week high | $8.90 | $1.60 |
| 52-week low | $0.91 | $0.281 |
| Distance from 52-week high | -82.87% | -82.44% |
| Analyst consensus | none | — |
| Avg. price target upside | +1014.75% | — |
| Average volume | 1.26M | 2.08M |
| Shares outstanding | 1.22M | 8.89M |
| Employees | 10 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Purple Biotech
PPBT stock →Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Redhill Biopharma
RDHL stock →RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
PPBT vs RDHL FAQ
Which is bigger, Purple Biotech or Redhill Biopharma?
Redhill Biopharma (RDHL) is larger, with a market capitalization of $2.50M compared with $1.86M for Purple Biotech (PPBT).
Are Purple Biotech and Redhill Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.